Literature DB >> 26114893

Impairment measures versus inflammatory RODS in GBS and CIDP: a responsiveness comparison.

Els K Vanhoutte1, Thomas H P Draak2, Kenneth C Gorson3, Sonja I van Nes4, Janneke G J Hoeijmakers2, W-Ludo Van der Pol5, Nicolette C Notermans5, Richard A Lewis6, Eduardo Nobile-Orazio7, Jean-Marc Léger8, Peter Y K Van den Bergh9, Giuseppe Lauria10, Vera Bril11, Hans Katzberg11, Michael P T Lunn12, Jean Pouget13, Anneke J van der Kooi14, Angelika F Hahn15, Pieter A van Doorn4, David R Cornblath16, Leonard H van den Berg5, Catharina G Faber2, Ingemar S J Merkies2,17.   

Abstract

This study aimed to 'define responder' through the concept of minimum clinically important differences using the individually obtained standard errors (MCID-SE) and a heuristic 'external criterion' responsiveness method in patients with Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). One hundred and fourteen newly diagnosed or relapsing patients (GBS: 55, CIDP: 59) were serially examined (1-year follow-up). The inflammatory Rasch-built overall disability scale (I-RODS), Rasch-transformed MRC sum score (RT-MRC), and Rasch-transformed modified-INCAT-sensory scale (RT-mISS) were assessed. Being-a-responder was defined as having a MCID-SE cut-off ≥1.96. Also, the correlations between patients' scores on each scale and the EuroQoL health-status 'thermometer' (external criterion) were determined (higher correlation indicated better responsiveness). In both diseases, the SEs showed a characteristic 'U'-shaped dynamic pattern across each scales' continuum. The number of patients showing a meaningful change were higher for the I-RODS > RT-MRC > RT-mISS and were in GBS higher than CIDP patients. The MCID-SE concept using Rasch-transformed data demonstrated an individual pattern of 'being-a-responder' in patients with immune-mediated neuropathies, and the findings were validated by the external criterion responsiveness method. The I-RODS showed greater responsiveness compared with the MRC and INCAT-sensory scales, and its use is therefore recommended in future trials in GBS and CIDP.
© 2015 Peripheral Nerve Society.

Entities:  

Keywords:  Rasch; immune-mediated neuropathies; minimum clinically important difference; outcome measure

Mesh:

Substances:

Year:  2015        PMID: 26114893     DOI: 10.1111/jns.12118

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN: 1085-9489            Impact factor:   3.494


  5 in total

Review 1.  Progress in inflammatory neuropathy -the legacy of Dr Jack Griffin.

Authors:  Eva L Feldman; Richard A C Hughes; Hugh J Willison
Journal:  Nat Rev Neurol       Date:  2015-10-13       Impact factor: 42.937

Review 2.  Comprehensive approaches for diagnosis, monitoring and treatment of chronic inflammatory demyelinating polyneuropathy.

Authors:  Anna Lena Fisse; Jeremias Motte; Thomas Grüter; Melissa Sgodzai; Kalliopi Pitarokoili; Ralf Gold
Journal:  Neurol Res Pract       Date:  2020-12-08

3.  Patient-reported symptoms and experience following Guillain-Barré syndrome and related conditions: Questionnaire development and validation.

Authors:  Aloysius Niroshan Siriwardena; Joseph N A Akanuwe; Vanessa Botan; Despina Laparidou; Ffion Curtis; Jennifer Jackson; Zahid B Asghar; Timothy L Hodgson
Journal:  Health Expect       Date:  2021-10-01       Impact factor: 3.377

4.  Analysis of relapse by inflammatory Rasch-built overall disability scale status in the PATH study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy.

Authors:  Ingemar S J Merkies; Ivo N van Schaik; Vera Bril; Hans-Peter Hartung; Richard A Lewis; Gen Sobue; John-Philip Lawo; Orell Mielke; David R Cornblath
Journal:  J Peripher Nerv Syst       Date:  2022-03-15       Impact factor: 5.188

5.  Assessing deterioration using impairment and functional outcome measures in chronic inflammatory demyelinating polyneuropathy: A post-hoc analysis of the immunoglobulin overtreatment in CIDP trial.

Authors:  Robin van Veen; Luuk Wieske; Ilse Lucke; Max E Adrichem; Ingemar S J Merkies; Ivo N van Schaik; Filip Eftimov
Journal:  J Peripher Nerv Syst       Date:  2022-05-25       Impact factor: 5.188

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.